Director David R. Epstein filed a Form 4 with the SEC on November 6, 2026, disclosing three open-market purchases of AgomAb Therapeutics NV common shares made on November 5, 2026, totaling 15,000 shares acquired at prices ranging from $6.81 to $6.98 per share.
Key Highlights
- Issuer: AgomAb Therapeutics NV, listed as NASDAQ:AGMB
- Reporting person: David R. Epstein, identified as a Director
- Transaction date: November 5, 2026, with the form filed November 6, 2026
- Three separate purchases: 5,000 shares at $6.81, 5,000 shares at $6.91, and 5,000 shares at $6.98, all coded as open-market purchases (code P)
- Total shares acquired: 15,000 common shares across the three transactions
- Beneficial ownership following transactions: 40,000 common shares held directly
- Share representation: According to the filing, common shares may be represented by American Depositary Shares, each of which currently represents one common share
Epstein's Three Open-Market Purchases of AgomAb Common Shares on November 5, 2026
According to the Form 4 filed with the SEC, David R. Epstein, a Director of AgomAb Therapeutics NV (NASDAQ:AGMB), conducted three separate open-market purchases of the company's common shares on November 5, 2026. The first purchase was 5,000 shares at a price of $6.81, bringing his reported beneficial ownership to 30,000 shares directly held. The second purchase was an additional 5,000 shares at $6.91, raising the total to 35,000 shares.
The third and final transaction on the same date was another 5,000 shares acquired at $6.98 per share, resulting in a post-transaction direct beneficial ownership of 40,000 common shares, as reported in the filing. All three transactions carry transaction code "P," indicating open-market purchases. The filing was signed by Ellen Lefever as attorney-in-fact on November 6, 2026.
The filing notes that the common shares may be represented by American Depositary Shares, each of which currently represents one common share. No derivative securities transactions were reported in Table II of the form. The filing was made by one reporting person, and no amendment date was indicated, suggesting this is an original filing.
What Was Disclosed
Director David R. Epstein disclosed three open-market purchases of AgomAb Therapeutics NV common shares on November 5, 2026, totaling 15,000 shares at prices between $6.81 and $6.98, resulting in direct beneficial ownership of 40,000 shares.



Please wait processing your request...